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Abstract: Multiple sclerosis (MS) is a neurodegenerative inflammatory disease where an autoimmune
response to components of the central nervous system leads to a loss of myelin and subsequent
neurological deterioration. People with MS can develop primary or secondary progressive disease
(PPMS, SPMS) and differentiation of the specific differences in the pathogenesis of these two courses,
at the molecular level, is currently unclear. Recently, lipidomics studies using human biofluids,
mainly plasma and cerebrospinal fluid, have highlighted a possible role for lipids in the initiation
and progression of MS. However, there is a lack of lipidomics studies in MS on CNS tissues,
such as normal-appearing white matter (NAWM), where local inflammation initially occurs. Herein,
we developed an untargeted reverse phase ultra-performance liquid chromatography time of flight
tandem mass spectrometry (RP-UPLC-TOF MSE)-based workflow, in combination with multivariate
and univariate statistical analysis, to assess significant differences in lipid profiles in brain NAWM
from post-mortem cases of PPMS, SPMS and controls. Groups of eight control, nine PPMS and seven
SPMS NAWM samples were used. Correlation analysis of the identified lipids by RP-UPLC-TOF
MSE was undertaken to remove those lipids that correlated with age, gender and post-mortem
interval as confounding factors. We demonstrate that there is a significantly altered lipid profile
of control cases compared with MS cases and that progressive disease, PPMS and SPMS, can be
differentiated on the basis of the lipidome of NAWM with good sensitivity, specificity and prediction
accuracy based on receiver operating characteristic (ROC) curve analysis. Metabolic pathway analysis
revealed that the most altered lipid pathways between PPMS and SPMS were glycerophospholipid
metabolism, glycerophosphatidyl inositol (GPI) anchor synthesis and linoleic acid metabolism.
Further understanding of the impact of these lipid alterations described herein associated with
progression will provide an increased understanding of the mechanisms underpinning progression
and highlight possible new therapeutic targets.
Keywords: multiple sclerosis; progression; lipidomics; neurodegeneration; glycerophospholipids
1. Introduction
Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative condition, which affects
more than 400,000 people living in the USA and approximately 2.5 million people worldwide [1].
The majority (85%) of MS patients are initially diagnosed in their third decade of life, with a relapsing and
remitting clinical course. In most of these patients, after 10–15 years of disease duration, relapsing/remitting
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MS (RRMS) develops into secondary progressive MS (SPMS) [2,3]. Approximately 15% of MS patients
however develop a progressive course from the onset, without preceding periods of relapse and remission,
known as primary progressive MS, (PPMS), with a peak onset in the fifth decade of life, which is similar
to the age when there is a conversion of patients with RRMS into SPMS [4,5]. It is currently not known
whether PPMS and SPMS are distinct entities or whether they could be phenotypic variations of the
same disease [6]. Whilst the inflammatory component of MS, which underpins relapses, is relatively well
understood, the progressive neurodegenerative phase of the disease, in both PPMS and SPMS, is yet to be
fully elucidated at the molecular level. Diffuse changes in normal-appearing white matter (NAWM) in the
central nervous system (CNS) reported in progressive disease, include axonal damage, microglial activation
and changes at the Node of Ranvier [7,8]. The neuronal/axonal damage and loss has been reported to
underpin the progression of disability in PPMS [9]. Understanding the underlying pathogenesis of clinical
progression in MS at the molecular and cellular level is vital for the development of therapies targeting the
neurodegenerative process.
Lipid metabolism has been suggested, previously to play a significant role in the pathophysiology of
MS [10,11]. Lipids involved in myelin formation and ensheathment of axons have been of most interest
to researchers investigating MS pathogenesis, considering the hallmark demyelinated plaques or lesions
in the CNS and the limited remyelination that takes place [8]. However, in addition to myelination,
lipids in the CNS have a diverse range of functions, including cell signalling, exosome formation and
cell-cell communication [12,13]. Laule et al. [14] described diffuse changes in the white matter (WM)
in MS were a result of a primary lipid abnormality. Subtle changes in the WM lipid components,
identified by our recent Raman spectroscopy data [15] highlight that apart from possibly impacting on
the molecular packing of myelin membranes, these changes may impact on critical cellular processes
involving lipids, which are vital for maintaining neural integrity and cell communication in the CNS.
There is an emerging body of previous metabolomic [16–23] and lipidomic [24–34] studies in MS
and its various forms (i.e., RRMS, PPMS, SPMS) and these mainly involve biofluids, such as plasma,
serum, cerebrospinal fluid (CSF), tears and urine, reviewed here [35,36]. Liquid chromatography
mass spectrometry (LC-MS) has been previously applied to the analysis of CNS lipids. However,
there is a lack of lipidomics reports on brain tissues such as NAWM, where the onset of MS disease
occurs, and more particularly studies that differentiate PPMS from SPMS based on their lipidomic
profile. Trepanier et al. [33] evaluated the concentration of oleic acid following demyelination and
remyelination in the cuprizone mouse model of MS, to test if these changes occurred in specific
lipid species. The group measured concentrations of fatty acids in total brain lipids and a panel of
lipid species with phosphatidylcholine (PC). Compared to control, oleic acid was decreased after
five weeks of cuprizone treatment and increased during the recovery phase. This decrease in oleic
acid was associated with a specific decrease in the PC (36: 1) pool. Wheeler et al. [37] showed that
despite no overall loss of lipid mass in MS NAWM and normal-appearing grey matter (NAGM)
tissue in human MS and control post-mortem cases, a reduction in sphingolipids (SLs) and a gain
in phosphatidylethanolamine (PE) species was observed using an electrospray ionization tandem
mass spectrometry (ESI-MS/MS) shotgun approach. Among lipids, increased CSF or blood levels
of cholesterol, which is an essential component of cell membranes and myelin, and its turnover
products, was reported to be associated with adverse outcomes in MS patients, based on a review of
21 studies [38]. Whereas omega-3 fatty acid, alpha-linolenic acid, was protective when fed to mice
with experimental autoimmune encephalomyelitis (EAE) and this was through preservation of the
blood brain barrier [39]. Thus, evidence from the literature indicates that alterations in the content and
levels of different lipid classes can influence disease progression in MS.
Herein, an untargeted reverse phase ultra-performance liquid chromatography time of flight
tandem mass spectrometry (RP-UPLC-TOF MSE)-based workflow, in conjunction with multivariate
(MVA) and univariate analysis, was developed, which can identify lipid alterations with high
sensitivity and specificity in WM from control and NAWM from PPMS and SPMS post-mortem
cases. We demonstrate that we can separate control cases from MS cases and that progressive disease,
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PPMS and SPMS, can be differentiated on the basis of the lipid profile of NAWM with good sensitivity,
specificity and prediction accuracy based on receiver operating characteristic (ROC) curve analysis.
Pathway analysis was also carried out revealing the most highly altered lipid pathways between PPMS
and SPMS were glycerophospholipid metabolism, glycerophosphatidyl inositol (GPI) anchor synthesis
and linoleic acid metabolism.
2. Results
2.1. Post-Mortem Case Details
Initially 12 blocks of tissue from each group, WM from controls and NAWM from SPMS and
PPMS, were screened by H&E, Oil red O and Luxol fast blue histological stains to ensure that blocks
with only WM or NAWM were selected. These were then further characterized using IHC to assess for
loss of MOG and expression of HLA DR to ensure the samples selected were histologically comparable.
Thus, following this screening process, white matter from nine control, and NAWM from eight PPMS
and seven SPMS cases were analysed. The clinical and demographic parameters of these cases are
listed in Table 1. All parameters (sex, age, PMI) did not differ significantly between pair-wise group
comparisons (i.e., PPMS vs. SPMS, controls vs. PPMS, controls vs. SPMS) after one-way ANOVA test
was performed. For sex, non-parametric test was performed (Kruskal–Wallis with post-hoc Tukey
test) whereas for age and PMI parametric test (ordinary one-way ANOVA with post-hoc Tukey test)
was applied.
Table 1. Demographic and clinical parameters of cases a.
Healthy Controls (n = 8) PPMS (n = 9) SPMS (n = 7) p-Value
Age (years) 76 ± 9 61 ± 10 60 ± 15 n.s.
Range (63–88) (39–73) (39–88)
Female/Male 2/6 6/3 6/1 n.s.
PMI (hours) 22.3 ± 8.5 14.6 ± 5.1 13.7 ± 6.3 n.s.
(5–33) (8–24) (7–24)
a Data are mean ± SD, (range). p-values for comparisons between the PPMS and SPMS groups. A one-way ANOVA
non-parametric (Kruskal–Wallis with post-hoc Tukey test) (sex) or parametric (ordinary one-way ANOVA with
post-hoc Tukey test) (age, PMI) test was used for calculating p-values. Abbreviations: PMI, post-mortem interval;
PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive multiple sclerosis; n.s., non-significant
(p > 0.05).
2.2. Immunohistochemistry of White Matter Tissue Sections
Microscopic assessment of all tissue blocks following IHC, demonstrated no change in
staining for myelin oligodendrocyte glycoprotein (MOG), which is expressed by oligodendrocytes,
the myelin-producing cells in the central nervous system and representative of intact myelin.
Microglia density and morphology, which was assessed by staining for the human leukocyte antigen
(HLA DR) were comparable between the three groups, indicative of a low level of inflammation, as HLA
DR plays a role in antigen presentation as part of the autoimmune response in MS. The IHC images
from a control case and an MS case for MOG and HLA-DR staining are provided in Supplementary
Figure S1 (Supplementary Materials). The images illustrate that there were no differences in staining
between the control normal cases and the MS case, which provided the basis for classification of
samples as normal-appearing white matter.
2.3. Multivariate Analysis of the RP-UPLC-TOF MSE Data
The QC samples were tightly clustered in the PCA scatter plot in both positive and negative
ion-mode (Figures 1A and 2A) showing that our lipidomics RP-UPLC-MSE method was valid,
producing high quality data for further downstream statistical analysis. The three groups were well
separated in the cross-validated OPLS-DA models (Figures 1B and 2B). Additionally, when pair-wise
comparisons were performed, all OPLS-DA models showed good separation between the two
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groups (Figure 1D–F and Figure 2D–F). The OPLS-DA permutation plot had low (negative)
value for Q2-intercept, confirming validation of the original model between the three groups
(Figures 1C and 2C). Permutation plots for all pairwise OPLS-DA models are shown in Figure S2A–C
(Supplementary Materials) (positive ion mode) and Figure S3A–C (Supplementary Materials) (negative
ion mode).
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Ions (features) derived from the OPLS-DA models were considered statistically significant when
they exhibited a VIP value of >1 and a p < 0.05 (Student’s t-test, unequal variance) in group pair-wise
comparisons. The raw data of the ions/features presented in Figure 3 are provided in the supplementary
data files (Excel files, Table S2a,b (Supplementary Materials)). From the Venn diagrams, the unique
ions/features that account for the separation of PPMS versus SPMS groups in positive and negative
mode (Figure 3A,B) were selected.
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Table 2. List of significant lipids identified in normal-appearing white matter (NAWM) that differentiate PPMS and SPMS groups by RP-UPLC-TOF MSE a. Lipids are
sorted in classes and listed alphabetically (ascending).
Peak
Number
MS
Mode RT m/z Adduct Lipid Identified Delta (ppm) p-Value FC
Trend (SPMS
vs. PPMS)
RSD(%)
in QCs
1 pos 14.38 778.6076 M + Na CerP (d18: 1/26: 1) −1.123 0.04439 1.210 ↑ 21.65
2 pos 6.93 621.4856 M + K DG (18: 0_15: 0) 0.176 0.00954 1.338 ↑ 11.19
3 pos 14.8 635.5615 M + H DG (18: 2_19: 0) 0.970 0.02617 1.387 ↑ 27.39
4 pos 0.61 429.2722 M + NH4 lysoPC (10: 0) −0.506 0.01166 2.144 ↑ 27.30
5 pos 1.84 527.3813 M + NH4 lysoPC (17: 0) −1.301 0.03450 0.775 ↓ 18.24
6 neg 6.21 514.3291 M − H2O − H lysoPE (22: 2) −2.182 0.01040 1.521 ↑ 24.22
7 neg 13.73 683.5004 M − H2O − H PA (18: 1_18: 0) −2.372 0.02982 1.182 ↑ 17.39
8 neg 10.15 779.5376 M + Cl PA (18: 1_21: 0) 1.749 0.00914 0.750 ↓ 27.26
9 neg 13.73 733.5153 M − H2O − H PA (20: 4_20: 0) −3.302 0.02392 1.418 ↑ 27.47
10 neg 6.77 885.6538 M + FA − H PA (22: 2_24: 0) −6.192 0.02793 0.709 ↓ 17.69
11 pos 9.79 746.4815n M + H, M + NH4 PA (22: 6_18: 1) −9.618 0.00450 0.762 ↓ 18.72
12 pos 8.43 821.5770 M + NH4 PC (20: 5_18: 2) −4.189 0.03984 1.497 ↑ 19.01
13 pos 13.66 794.6051 M + Na PC (P-18: 0_18: 1) 2.244 0.01342 0.747 ↓ 12.38
14 neg 13.66 780.593 M − H2O − H PE (18: 1_22: 1) 2.113 0.02526 0.745 ↓ 25.62
15 neg 7.64 696.5034 M − H2O − H PE (18: 2_16: 0) 8.412 0.00112 0.587 ↓ 21.90
16 neg 11.22 820.5576 M + Cl PE (18: 2_21: 0) −6.698 0.01061 0.796 ↓ 13.39
17 neg 8.92 832.564 M + Cl PE (18: 2_22: 1) 1.436 0.01213 0.793 ↓ 26.52
18 neg 13.51 766.5446 M − H PE (20: 2_18: 2) 7.043 0.00175 0.702 ↓ 17.09
19 neg 13.57 792.5594 M − H PE (20: 3_20: 2) 5.652 0.01380 0.756 ↓ 27.45
20 neg 13.93 806.6094 M − H2O − H PE (20: 3_22: 0) 3.015 0.01864 0.745 ↓ 18.16
21 neg 8.49 812.5500 M + FA − H PE (20: 4_18: 0) 6.873 0.00507 0.515 ↓ 18.51
22 neg 10.28 840.5818 M + FA − H PE (20: 4_20: 0) 7.300 0.02022 0.660 ↓ 11.71
23 neg 7.71 702.5488 M − H PE (P-16: 0_18: 0) 6.340 0.01840 0.772 ↓ 18.57
24 neg 7.57 696.4689 M + Cl PE (P-18: 0_13: 0) −7.776 0.00027 0.528 ↓ 28.00
25 neg 7.78 762.5722 M + FA − H PE (P-18: 0_17: 0) 9.407 0.01114 0.764 ↓ 13.19
26 neg 13.51 796.5545 M + FA − H PE (P-18: 0_20: 4) 6.307 0.02060 1.223 ↑ 27.33
27 neg 10.93 794.5401 M + FA − H PE (P-18: 0_20: 5) 7.929 0.00260 1.300 ↑ 16.75
28 neg 11.58 820.597 M + Cl PE (P-18: 0_22: 1) −2.904 0.00037 0.723 ↓ 18.92
29 neg 10.44 802.5798 M − H PE (P-20: 0_22: 6) 5.269 0.00039 0.663 ↓ 9.27
30 neg 10.51 785.5129 M + Cl PG (18: 0_16: 0) 3.202 0.00092 1.751 ↑ 10.77
31 neg 10.93 811.5285 M + Cl PG (18: 1_18: 0) 3.008 0.00076 1.485 ↑ 16.55
32 neg 6.21 847.5457 M − H PG (22: 6_20: 1) −4.431 0.00073 0.573 ↓ 21.41
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Table 2. Cont.
Peak
Number
MS
Mode RT m/z Adduct Lipid Identified Delta (ppm) p-Value FC
Trend (SPMS
vs. PPMS)
RSD(%)
in QCs
33 neg 4.35 905.5312 M + FA − H PI (18: 2_18: 1) −9.876 0.03147 0.751 ↓ 10.79
34 neg 12.43 889.5749 M − H PI (22: 2_16: 0) −7.040 0.00121 0.702 ↓ 11.41
35 neg 10.08 878.6138 M + FA − H PS (18: 0_21: 0) 1.210 0.01828 0.700 ↓ 16.67
36 neg 8.56 792.5255 M − H2O − H PS (18: 1_20: 3) 8.655 0.00255 1.626 ↑ 19.32
37 neg 9.28 826.5966 M − H2O − H PS (18: 1_22: 0) −0.113 0.00101 0.701 ↓ 14.02
38 neg 9.14 916.6283 M + FA − H PS (18: 1_24: 1) −0.160 0.00014 0.546 ↓ 16.38
39 neg 7.78 876.5505 M + Cl PS (18: 2_22: 1) −2.583 0.00258 0.641 ↓ 19.13
40 neg 7.84 816.5792 M − H PS (20: 1_18: 0) 3.884 0.04284 0.717 ↓ 14.43
41 neg 9.28 890.5644 M + Cl PS (20: 3_21: 0) −4.546 0.00035 0.647 ↓ 22.84
42 neg 11 862.4866 M + FA − H PS (22: 6_17: 2) −1.232 0.00484 1.390 ↑ 24.58
43 neg 12.14 880.5401 M + FA − H PS (22: 6_18: 0) 6.702 0.04395 0.844 ↓ 18.81
44 neg 10.93 811.4895 M + FA − H SQDG (18: 0_12: 0) 1.591 0.02255 1.306 ↑ 26.20
a CerP, ceramide 1-phosphate; DG, diacylglycerol; PA, phosphatidylanisol; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol;
PS, phosphatidylserine; SQDG, sulfoquinovosyl diacylglycerols. p-value of t-test (two-tailed, unequal variance) between PPMS and SPMS; FC, Fold change, SPMS versus PPMS;
↑, increased in SPMS compared to PPMS; ↓, decreased in SPMS compared to PPMS.
Table 3. List of common significant lipids identified in the normal-appearing white matter (NAWM) by RP-UPLC-TOF MSE that differentiate control from PPMS,
and controls from SPMS groups. Lipids are sorted in classes and listed alphabetically (ascending).
p Value FC Trend
Peak
Number
MS
Mode RT m/z Adduct Lipid Identified
Delta
(ppm)
CON
a-PPMS CON-SPMS PPMS/CON SPMS/CON PPMS/CON SPMS/CON
RSD%
in QCs
1 pos 3.05 719.5589 M + Na DG (20: 4_22: 2) 0.526 0.0448 0.0238 0.875 0.853 ↓ ↓ 15.86
2 pos 8.36 704.5254 M + NH4 PA (18: 2_17: 0) 4.296 0.0096 0.0025 0.796 0.731 ↓ ↓ 15.57
3 pos 6.28 738.5091 M + NH4 PA (20: 5_18: 1) 3.127 0.0376 0.0102 0.585 0.472 ↓ ↓ 17.74
4 neg 12.14 752.5621 M − H2O − H PE (18: 2_20: 0) 2.771 0.0003 0.0065 1.553 1.540 ↑ ↑ 25.34
5 neg 13.86 840.5768 M + FA − H PE (20: 4_20: 0) 0.943 0.0017 0.0020 1.306 1.315 ↑ ↑ 17.26
6 neg 8.72 828.5276 M + Cl PE (20: 4_20: 1) −5.046 0.0105 0.0053 0.589 0.549 ↓ ↓ 25.55
7 neg 10.71 882.5863 M + Cl PE (22: 6_22:0) 9.208 0.0444 0.0164 0.671 0.588 ↓ ↓ 24.42
8 neg 8.2 819.5428 M − H2O − H PI (18:0_16:0) 4.231 0.0163 0.0079 0.621 0.583 ↓ ↓ 21.29
9 neg 8.36 846.5546 M + FA − H PS (18:2_19:0) 5.461 0.0102 0.0092 0.786 0.799 ↓ ↓ 15.08
10 neg 8.85 880.5744 M + FA − H Sulfatide (d18: 1/20: 0) −9.753 0.0111 0.0040 0.759 0.729 ↓ ↓ 20.69
DG, diacylglycerol; PA, phosphatidylanisol; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine. p-value of t-test (two-tailed, unequal variance) between
PPMS/SPMS and controls; FC, Fold change; ↑, increased in PPMS/SPMS compared to controls; ↓, decreased in PPMS/SPMS compared to controls. a CON, controls.
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2.4. Markers of Progression between PPMS and SPMS
After following all the steps in the lipidomics workflow described in 3.2, 44 lipids were identified
as significant markers of progression in PPMS compared to SPMS (Table 2). Overall, most of these
lipid levels (29/44 or 65.9%) were decreased in SPMS compared to PPMS, while 15/44 (or 34.1%) were
increased in SPMS compared to PPMS. Additionally, when lipids were sorted by class, mixed mode
effects were observed. All 9 phosphatidylethanolamines (PEs) were decreased in SPMS compared to
PPMS, as well as the majority (5/7) of putative PE-plasmalogens (PE-P). These are putative assignments
as the location of the double bonds with respect to the ether linkage cannot be assigned. Future
experiments using specially designed LC-MS methods can confirm these assignments. Regarding other
phospholipids (PLs), i.e., phosphatidylanisols (PA), phosphatidylinositols (PI), phosphatidylserines
(PS), again the same trend of lower levels in SPMS was observed for the majority of lipids; 3/5 PA, 7/9 PS,
and 2/2 PI had decreased levels in SPMS. On the contrary, amongst the lipids that exhibited higher levels
in SPMS (compared to PPMS) were 1 ceramide (Cer), 3 diacylglycerols (DG), 2/3 phosphatidylglycerols
(PG), 1/2 phosphatidylcholines (PCs), and 2/3 lysophosphatidyl lipids (lysoPLs). Notably, all 44 lipids
exhibited peak areas with RSD < 30% in the QC samples; 28/44 (or 63.6%) lipids had RSD < 20% in the
QCs, which shows that these 44 significantly altered lipids in SPMS versus PPMS are stable throughout
the LC-MS analysis time, which spanned over four days.
Furthermore, although the fold change (FC) between SPMS and PPMS was small for the majority
of lipids, when the lipids were investigated together, they formed a “lipid signature” that could
provide further information about the possible different mechanisms of disease progression between
PPMS and SPMS. Notably, 4 lipids had a FC > 1.5 (lysoPC (10:0), PG (18:0_16:0), PS (18:1_20:3) and
lysoPE (22:2)), in SPMS versus PPMS, with two of them being lysoPLs (lysoPC and lysoPE); this shows
that lysoPLs are highly abundant in SPMS (compared to PPMS) to a much higher degree than the
other significant lipids. Additionally, the three most abundant lipid classes are PE, PS and PLs-P. PE,
phosphatidylethanolamines; PS, phosphatidylserines; PLs-P, putative plasmalogens as can be observed
in the pie chart below (Figure 4).
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2.5. Lipid Markers of Progression in MS Compared with Control Cases
Ten lipids were found to be common and statistically significant for the separation of controls and
PPMS, and the separation of controls and SPMS, after applying the same lipidomics workflow: seven
lipids in negative ion mode and three lipids in positive ion mode. Of all 10 lipids, most of them in both
SPMS and PPMS NAWM, demonstrated the same trend when compared with control WM samples.
As can be seen in Table 3, the levels of 8/10 lipids were lower in both PPMS and SPMS compared to
controls, while 2/10 lipids were found to be increased in both PPMS and SPMS in relation to the control
group. The two lipids that increased in PPMS and SPMS were identified as PE (18:2_20:0) and PE
(20:4_20:0). PE (20:4_20:0) contains one fatty acid (FA) with a 20-carbon chain and four double bonds;
this FA is assigned to eicosanoid arachidonic acid (AA) which is an omega-6 (n-6) polyunsaturated
fatty acid (PUFA).
Furthermore, the 8 lipids that were attenuated in both PPMS and SPMS compared to controls,
were identified as PA, PE, PI, PS, DG and sulfatide. Most of these lipids (five out of eight), contain in
their structure the FAs 18:0, 18:1 and 18:2, which are the three most abundant FAs in human
plasma [40]. Additionally, PE (22:6_22:0) and PA (20:5_18:1) contain the FAs 22:6 and 20:5, which are
assigned to oxylipins (pro-resolvins) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).
Lastly, our lipidomics workflow revealed the presence of odd chain saturated fatty acids (OCS-FAs)
incorporated in phospholipids, such as PA (18:2_17:0) and PS (18:2_19:0).
2.6. ROC Analysis
ROC curve analysis was performed to validate the OPLS-DA analysis and test the applicability
of statistically differential lipids in separating PPMS and SPMS. Figure 5A,C show a group of ROC
curves for models established by using different lipids selected by the filter approach. Six models were
generated for both positive (Figure 5A) and negative (Figure 5C) ion mode. For positive ion mode,
the top two lipids lysoPC (10:0) and PC (20:5_18:2) were used to build classification model 1; the area
under the curve (AUC) value was 0.776 and the 95% confidence interval (CI) was 0.557–0.975. When all
seven lipids were used, the AUC value was 0.868, while sensitivity was 77.8%, specificity of 92.6%
and predictive accuracy of 81%. For negative ion mode, when all 34 lipids were used the AUC value
was 0.844, sensitivity was 66.7%, specificity of 83.3% and predictive accuracy of 74.4%. Based on the
selected significant lipids, ROC curve analysis revealed that the two OPLS-DA models identified lipid
markers of progression in NAWM, sorted by their importance (Figure 5B,D) and these account for the
differences between PPMS and SPMS.
2.7. Metabolic Pathway Analysis
Lipid species identified as potential markers (positive and negative ion mode combined) of
progressive disease in NAWM were related to glycerophospholipid metabolism [PC, PE, LysoPC (18:1)],
glycosylphosphatidylinositol(GPI)-anchor biosynthesis (PE), linoleic acid (PC), alpha-linolenic acid
(PC) and arachidonic acid metabolism (PC) (Figure 6). The pathways were considered as the metabolic
routes most significantly altered in PPMS compared to SPMS, based on a combination criteria of lowest
p values (p < 0.05) in the y-axis and pathway impact in the x-axis. Glycerophospholipid metabolism
was the most significantly altered pathway between PPMS and SPMS.
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2.8. Correlation Analysis of Lipid Levels with Sex, Age, and PMI
As stated previously, several identified lipids which were found to be significantly altered between
PPMS and SPMS, and for which an HMDB or LIPIDMAPS ID number was associated with their
name, were correlated with sex, age, and PMI. In total, levels of 32 lipids were found to be correlated
with at least one of these parameters. Of these 32 lipids, 17 lipids were correlated with age, 14 lipids
correlated with PMI and two lipids with sex. More specifically, most lipids that were correlated with
age showed a positive correlation (12/17 or 70.6%) while 5/17 (or 29.4%) showed a negative correlation.
Of the 14 lipids statistically associated with PMI, 12/14 (or 85.7%) were negatively correlated with PMI,
while two lipids showed a positive correlation. Lastly, of the two lipids that were associated with sex,
PE (P-18:0_22:1) was statistically increased in females while PE (18:3_21:0) had significantly higher
levels in males. A detailed description of these 33 lipids and their correlation with sex, age and PMI is
given in Supplementary File, Table S3 (Supplementary Materials).
3. Discussion
Lipidomics is a powerful tool for the study of neurological diseases such as MS [41]. It has
been used to determine subtle changes in the lipidome of biofluids and tissues from MS cases
when compared with healthy control samples [24,27,29,34]. Recent lipidomic and metabolomics
studies have also investigated different forms of MS, however there is a lack of lipidomic studies on
differentiating PPMS from SPMS. Although different biofluids that could be used as biomarkers for
MS were studied for their lipidomic profile, to the best of our knowledge there are no lipidomics
reports on CNS tissue, including NAWM, where early molecular changes, prior to the onset of disease,
could be detected. This becomes even more evident considering the wealth of information available
from previous immunohistology reports [42,43]. More importantly, imaging mass spectrometry
(IMS) techniques (i.e., MALDI-MS, LESA-MS, DESI-MS) have very recently proven to be effective in
investigating the lipidome of various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s,
and MS, reviewed here [44]. Thus, spatiotemporal lipid changes in brain tissues can be mapped to
monitor the progression of disease, as was recently described by Bergholt et al. [45] for MS. Therefore,
lipid biomarkers from homogenates of NAWM, using a RP-UPLC-TOF MSE method, can be compared
and complement lipidomics data from IMS studies, providing a deeper insight into the role of lipids in
progression of MS disease.
In this study, we developed an untargeted lipidomics workflow based on RP-UPLC-TOF MSE
method, combined with MVA and univariate statistical analysis, to demonstrate that NAWM from
PPMS and SPMS post-mortem cases, can be differentiated based on their lipidomic profile, but also
when compared with healthy control white matter post-mortem samples. After applying the lipidomics
workflow developed here, the identified significantly altered lipids between PPMS and SPMS,
and between both PPMS and SPMS compared to controls, belong to three key families: (a) sphingolipids,
(b) phospholipids, and (c) glycerolipids. To the best of our knowledge this is the first report of altered
lipid profiles in NAWM comparing PPMS and SPMS cases using lipidomic methods. Most recent
studies focus on differentiating mainly RRMS and SPMS, using biofluids. Herein, we discuss the key
differences and the role of these significantly altered lipid families in PPMS and SPMS NAWM and
control WM.
Phospholipids are the main class of lipids shown in our study to differentiate between the two forms
of MS progression. More specifically, 40 out of 44 significant lipids belong to this class, which comprises
different subclasses: PC, PE, putative plasmalogens PC and PE (PC-P, PE-P), phosphatidic acids (PA),
phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserines (PS) and lysophospholipids
(lysoPLs), lysoPE and lysoPC. Twenty-nine out of 44 phospholipids (66%) were decreased in SPMS
compared to PPMS NAWM post-mortem brain samples, while 34% were increased in SPMS compared
to PPMS.
Phospholipids are the most abundant lipid class present in human plasma [46]. Recent studies
have demonstrated that phospholipids can discriminate between MS and healthy control CSF and
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plasma. The group of Stoessel in 2018 reported reduced levels of five PCs and four lysoPCs in plasma of
PPMS patients compared to healthy controls, sex and age matched, using a metabolomic approach with
LysoPC (20:0) being statistically decreased in the MS cohort over a 24-month period [23]. In addition,
an untargeted LC-MS approach was performed by Nogueras et al. [27] to determine global lipidomic
differences in the CSF between MS and non-MS patients, i.e., those who had had a lumbar puncture
but the diagnosis was not MS. Forty seven lipid species were identified, among which there were
30 glycerolipids, five sterol lipids, four FAs and five phospholipids (PC, PE, and PS). Another study
reported that alpha-linolenic acid administered to mice with EAE was protective against the disease
through reducing the permeability of the blood brain barrier [47]. Furthermore, Pieragostino et al.,
in 2015, analysed the hydrophobic metabolites of MS and other neurological disease (OND) patients’
CSF using MALDI-TOF mass spectrometry [30]. Their studies demonstrated altered levels of specific
phospholipids in the MS group compared to the OND group. They reported a significantly increased
level of lysoPC (18:1), lysoPC (18:0), and lysoPI (16:0) in the CSF of MS patients. LysoPC levels correlated
to the IgG Index, indicative of breakdown of the blood brain barrier. Additionally, the levels of lysoPI
in MS were negatively correlated to the Expanded Disability Status Scale (EDSS) score suggesting
that increased levels of lysoPI (16:0) in CSF could exhibit a protective role against development of
neurological symptoms in MS patients. In the current study, analysis of NAWM from PPMS and SPMS
samples found lysoPC (10:0) and lysoPE (22:2) were significantly increased in SPMS compared to
PPMS (2- and 1.5-fold, respectively), whereas lysoPC (17:0) was decreased by 22.5%. Further analysis
of the function of these lipids in the CNS is required to fully understand the implications of these
changes in tissues.
Furthermore, PC is the major phospholipid species of eukaryotic membranes and removal of one
of the fatty acids results in generation of lysoPC via the phospholipase A2 (PLA2) enzyme. It has been
previously reported that PLA2 products are involved in various pathways, such as signal transduction,
biosynthesis of inflammatory mediators, differentiation and apoptosis [48]. There is evidence that a
deregulation of PLA2 and its products has been associated with various neurodegenerative diseases,
such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis [49]. The therapeutic
effect of Fingolimod, a sphingosine-1-phosphate (S1P) analogue approved for treatment of MS patients,
acts via inhibition of PLA2 activity in the CNS [50]. Therefore, it is suggested that the pathological
overstimulation of PLA2 contributes to releasing lysoPCs from membrane phospholipids, resulting in
accumulation of lysoPC species in brain tissue, confirmed by high levels of lysoPCs in CSF of MS
patients [23]. Herein, we found that of the two lysoPCs identified as significantly different between
PPMS and SPMS, one was upregulated and the other downregulated, which confirms their complex
role in progression of MS.
The myelin sheath is extremely rich in sphingolipids and glycerophospholipids [51].
Approximately 70–85% of the myelin dry weight is lipids [52]. The major FAs observed in myelin
are stearic acid [FA (18:0)] and palmitic acid (FA (16:0)), saturated fatty acids, as well as oleic acid
(FA (18:1)), a monounsaturated fatty acid [53,54]. Previous studies have shown a decrease in oleic
acid (FA (18:1)) in the WM of post-mortem brain of MS cases compared to healthy controls [55,56].
FAs are the building blocks that incorporate into the glycerol backbone of membrane phospholipids,
comprising the sn-1 and sn-2 side chains. It was observed in the current study that 11/44 (25%) of
significantly altered lipids (PPMS vs. SPMS) have oleic acid (FA (18:1)) side chains. Seven out of 11
(63.6%) oleic acid moieties incorporated in phospholipids are decreased in SPMS vs. PPMS; this agrees
with these previous reports, when WM from MS cases were compared with control cases [55,56].
Although we did not perform a targeted FA profile here (commonly performed by GC-MS), thereby the
exact FA structure could only be tentatively identified, the fact that FA (18:1) is one of the most highly
abundant FA in human myelin would support its identification here.
Glycerolipids also showed differences in lipid profiles between PPMS and SPMS cases. Specifically,
an upregulation of diacylglycerols (DG) in SPMS vs. PPMS was determined. This finding could be
linked with a defect of the diacylglycerol acyltransferase (DGAT) enzyme, which, in turn, is related
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to insulin resistance, an observation recently seen in patients with MS [57,58]. Also, a recent study
revealed that inhibition of DGAT enzyme blocked the accumulation of lipid droplets consisting of
neutral and phospholipids measured by LC-MS in cell cultures of murine cortical astrocytes [59].
DGAT catalyses the final acylation step in the triaclyglycerol (TG) biosynthetic pathway by transferring
a fatty acyl group from acyl-CoA to the sn-3 position of diacylglycerol to form TG. Although this study
compared controls versus MS patients and not SPMS vs. PPMS, it is indicative of the role of DGAT
enzyme in MS and subsequently an indirect role for DG in MS.
Sphingolipids were the third class of lipids that was found to differentiate between PPMS and
SPMS. Sphingolipids are integral components of biomembranes, which are involved in many cellular
functions, including cell proliferation, signalling cascades and apoptosis [60]. Sphingolipids include
sphingomyelins (SMs), ceramides and sphingosines, involved in the same pathway, by sequential
enzymatic reactions [48]. It is noteworthy that fingolimod, which as mentioned beforehand here, is an
antagonist of sphingosine-1-phosphate and is an effective treatment for MS [61]. This highlights the
importance of this lipid family in MS, levels of which we have demonstrated to be altered in NAWM
between PPMS and SPMS. Moreover, patients with MS have a higher level of ceramide C16:0 and
C24:0 in the CSF, which may be linked to the axonal damage observed in the disease [62]. Ceramide is
produced in the CSF through the hydrolysis of sphingomyelin. In addition, lower sphingolipid content
was found in NAWM from MS cases compared to controls [37], while sphingosine content is increased
in MS NAWM [63]. Although there are no previous reports on differences in ceramide levels between
SPMS and PPMS patients in NAWM, the abovementioned studies clearly demonstrate the key role of
ceramides in MS.
Hence, our results agree with other studies that have found alterations in lipids, such as ceramides
in CSF [64], brain PCs [33] and sphingolipids in the WM of the brain [37]. Finally, NAWM in human
brain tissue [33] is composed mainly of PCs and PEs, levels of which differed between PPMS and SPMS
groups in our study. Overall, lipid level alterations in NAWM could reflect alterations in the lipid
composition of the myelin sheath as well as cell membranes of neurons and glia, revealing underlying
mechanisms in the progression in MS. One limitation of this study could be the number of cases
examined and that samples were post-mortem brain tissues, although any lipid changes linked to
post-mortem interval (PMI) were removed from the study. Hence, lipid markers of MS progression
identified here cannot be used for biofluid biomarkers between PPMS and SPMS, although these
should be further investigated in for example CSF to assess their potential as biomarkers of disease.
However, we demonstrate herein that our approach could distinguish PPMS from SPMS cases, but
also PPMS and SPMS from controls, based on their lipidomic signature in CNS tissue; these findings
could complement and add more validation to lipid biomarkers proposed in other lipidomics studies
of biofluids.
A group of 10 lipid markers were identified to separate controls from progressive forms of
MS (PPMS and SPMS), whereas 44 lipids were significantly altered between PPMS and SPMS.
Different panels of significant lipids were hence found to account for these separations; however,
it should be noted that phospholipids were the dominant differentiating lipid species for both
comparisons. Lastly, odd chain saturated fatty acids (OCS-FAs) incorporated in phospholipids, such as
PA (18:2_17:0) and PS (18:2_19:0), were among the significant lipids differentiating controls from
PPMS and SPMS. Although these lipids were considered of non-mammalian origin, there is emerging
evidence that increased consumption of dairy products has an association with an increase in blood
plasma OCS-FAs [64,65].
Therefore, although the scope of our study focused on finding markers to differentiate PPMS and
SPMS, our data favour that semi-targeted lipidomics UPLC-MS/MS approaches (i.e., phospholipid
profiling) would be beneficial in studying progressive MS. These approaches would aid in a more
comprehensive discovery of both diagnostic and prognostic markers of MS disease, ultimately aiding
to unravel the complex mechanisms that govern progressive MS disease.
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4. Materials and Methods
4.1. Post-Mortem CNS Cases
The human brain tissue used in this study was provided by the UK MS Society Tissue Bank,
Imperial College, London, UK. Ethical approval for the collection of the post-mortem tissue samples
was approved by Wales Research Ethics Committee (reference number 08/MRE09/31) and Sheffield
Hallam University, Faculty of Health and Wellbeing Research Ethics Committee approved the study.
The summarized characteristics of the cases used in this study are detailed in Table 1, with information
for each case provided in supplementary data (Table S1 (Supplementary Materials)).
4.2. Acquisition of Lipidomic Data
4.2.1. Analytical Standards
LC/MS grade Acetonitrile (ACN) and isopropanol (IPA) was obtained from Fisher Scientific
(Loughborough, UK). Distilled Water (18.2 MW) for chromatographic separation was purified in a
Milli-Q device (Millipore, Merch Darmstadt, Germany). Ammonium formate (NH4HCO2) and formic
acid were purchased from Sigma Aldrich (Gillingham, UK). PBS solution and bovine serum albumen
(BSA) powder were purchased from Fisher Scientific (Loughborough, UK). Monoclonal antibody
(anti-HLA-DR) was purchased from Abcam (Cambridge, UK) while the avidin biotin peroxidase
complex ABC kit and peroxidase substrate were obtained from Vector Laboratories (Peterborough, UK).
4.2.2. CNS Sample Collection
White matter (WM) from control (CON) cases (n = 8) and NAWM from MS post-mortem cases,
PPMS (n = 9) and SPMS (n = 7) were included in the study. Confirmation of the classification of MS
cases as primary or secondary progressive was obtained by the MS Society Tissue Bank neurologists’
assessment of the patient clinical notes pre-mortem. Serial 30 µm sections were acquired in a cryostat
(Leica, UK) and were transferred into cold (−20 ◦C) pre-labelled and weighed Eppendorf tubes.
Tissue weights collected were in the range of 10–20 mg and these were stored at −80 ◦C, until used for
lipid extraction. For each brain block sample, three biological replicates were acquired. Serial sections
(10 µm) from each block were collected on polysine coated glass slides (VWR, Lutterworth, UK) and
stored in airtight containers at −80 ◦C until required for histology and immunohistochemistry (IHC).
4.2.3. Classification of WM and NAWM Tissue Using Histological and Immunohistochemical Techniques
Serial frozen sections (10µm) were used to (a) assess that only WM was acquired for analysis, based
on Hematoxylin and Eosin (H&E) and Oil Red O and Luxol Fast Blue staining to ensure no evidence
of demyelination and (b) confirmation of this by IHC was performed with a monoclonal antibody to
myelin oligodendrocyte glycoprotein (MOG) (provided by Professor C. Linington, Glasgow University)
and to assess the extent of any inflammation, evidenced by activation of microglia, using increased
expression of human leukocyte antigen (HLA-DR) with a monoclonal antibody, Abcam (Cambridge,
UK), and to identify any change in morphology of resident microglia. Negative controls were
obtained by replacement of the primary antibody with PBS with 0.05% bovine serum albumen (BSA).
The avidin biotin peroxidase (ABC, Vector Laboratories, Peterborough, UK) method was used with
diaminobenzidine as substrate, producing a brown positive stain, and hematoxylin counterstain,
providing a blue nuclear stain as described previously [66]. Slides were assessed by two independent
observers. Where there was any discrepancy between the observers, the sections were observed jointly
to reach an agreed decision of the classification of normal and NAWM. Any tissue blocks that did not
meet this classification were excluded from downstream analysis.
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4.2.4. Lipid Extraction from White Matter
Lipid extraction was performed as described in a recent publication [67], with minor modifications
as follows. Brain tissues in Eppendorf tubes were briefly centrifuged for 2 min at 4000× g, at 4 ◦C.
Methanol was added to each tube and the volume adjusted for each sample weight to ensure a consistent
volume/weight ratio. Tissues were vortex-mixed for 40 s, followed by disruption and homogenization
in a TissueLyser LT (Qiagen, Manchester, UK) for 2 min at 30 Hz at room temperature. A volume of
200 µL of homogenate was recovered from each tube and transferred into clean Eppendorf tubes. Then,
400 µL of chloroform was added and the sample vortexed for 30 s, followed by addition of 150 µL
of water and vortex for 30 s. After a final centrifugation step at 4000× g for 10 min at 4 ◦C, the lower
organic phase containing the extracted lipids was recovered and transferred into clean Eppendorf tubes.
The samples were then dried using a vacuum concentrator 5301 (Eppendorf, Hamburg, Germany)
for 60 min at 35 ◦C. Dried extracts were reconstituted in isopropanol (IPA)/acetonitrile (ACN)/water
(4:3:1 v/v/v, 100 µL). A quality control (QC) sample was prepared by pooling aliquots (25 µL) of each
processed tissue, 24 in total. Samples were transferred to brown glass autosampler vials and stored at
−80 ◦C until LC-MS analysis.
4.2.5. UPLC–MS Data Acquisition
A detailed protocol of the RP-UPLC–TOF MSE parameters and instrumentation was recently
described and adopted [68]. Briefly, a 20 min gradient mobile phase system was employed using
a UPLC binary solvent manager. The mobile phase A consisted of ACN/water (60:40), 10 mM
NH4HCO2, and 0.1% formic acid and mobile phase B of IPA/ACN (90:10), 10 mM NH4HCO2 and 0.1%
formic acid. The flow rate was set at 0.4 ml/min, the injection volume to 3 µL and the autosampler
temperature to 4 ◦C. The gradient profile was set as follows: 60–57% A (0.0–2.0 min), 57–50% A (2.0–2.1
min; curve 1), 50–46% A (2.1–12.0 min), 46–30% A (12.0–12.1 min; curve 1), 30–1% A (12.1–18 min),
1–60% A (18.0–18.1 min) and 60% A (18.1–20.0 min). An Acquity UPLC CSH C18, analytical column
(2.1 × 100 mm, 1.7 µm) (Waters Corp, Milford, MA, USA) was used for chromatographic separation
and maintained at 55 ◦C. Mass spectrometry was performed on a Waters Xevo G2-XS QTof (Waters
Corp, Milford, MA, USA) equipped with an electrospray ionization (ESI) source in positive- and
negative-ion mode. The electrospray voltage was 3 kV (−3 kV for negative), the cone voltage was 30 V,
the source temperature was 120 ◦C and the desolvation temperature was set to 450 ◦C. Nitrogen was
used as both desolvation gas (flow rate, 580 L/h) and the cone gas (50 L/h). Two parallel alternating
scans were employed for low collision energy and high collision energy acquisition. Scan for low
collision energy was set to 50–1200 m/z. The high collision energy scan was performed without ion
selection (MSE channel) [69]. The QC samples were run four times before the test sample sequence to
stabilize the LC-MS system, and subsequently after every fifteen sample injections.
4.3. Data Processing and Lipid Identification
Acquired UPLC-MS data were processed using Progenesis QI (v.2.2) software (Nonlinear Dynamics,
Newcastle upon Tyne, UK), for peak detection, alignment, deconvolution, ion filtering,
compound identification and normalization using total area of features identified by the software.
Ion filtering based on QCs was used. More specifically, an ion had to meet the following criteria
to be selected for further downstream statistical analysis: (a) to have a CV <30% of peak areas in
QCs, and (b) to follow the 80% rule, i.e., an ion had to have at least non-zero intensities in >80%
for each group (controls, PPMS and SPMS samples) [70–72]. The retention times (RTs), m/z values
and corresponding peak intensities were imported into SIMCA-15 (Sartorius Stedim Data Analytics
AB, Umeå, Sweden) for MVA. Principal component analysis (PCA) and orthogonal partial least
squares−discriminant analysis (OPLS-DA) were performed to investigate differences in lipidomic
profile among the groups [73,74]. The variables of importance in the project (VIP) values [75] followed by
two-tailed Student’s t-test (unequal variance) were used to identify significant lipids for pair-wise group
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comparisons (i.e., controls vs. PPMS, controls vs. SPMS, and PPMS vs. SPMS), adopting the protocol
described in [76]. A p-value < 0.05, without corrections for multiple comparisons, between means of
each pair-wise group comparison for each ion was used in order to detect as many lipids as possible,
that would be meaningful if there were different clusters from separate classes found as potential
biomarkers, as was the case. In addition, having three groups to compare, as opposed to the more
standard two-group comparisons in a control vs. disease case, decreases the number of potential
unique biomarkers, in the comparison between PPMS vs. SPMS disease. Notably, we adopted this
strategy from a recent publication using metabolomics to identify biomarkers in drug induced liver
injury, where the group also had three human patient groups to compare see reference [76].
The lipidomics workflow is depicted in Figure 7. For lipid structure assignment, accurate m/z
measurements were matched to the accurate mass of lipids from online metabolomics databases,
i.e., METLIN [77], HMDB v.4 [78], and LIPID MAPS [79]. After an assessment of retention time,
experimental tandem MS spectra (MSE) were compared against MS/MS fragmentation patterns available
in LIPIDBLAST [80,81] library embedded in PROGENESIS QI (v.2.2) (Nonlinear Dynamics, Newcastle
upon Tyne, UK), software. Future work should validate these assignments using the MS/MS raw data.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/9/366/s1,
Figure S1: Immunohistochemistry for myelin using anti-MOG antibody (A,B) and microglia stained with
anti-HLADR antibody (C,D) on frozen sections of Control (A & C) (case 39) and MS (case 275) samples. Sections are
counterstained with haematoxylin (blue). Bar represents 50 µm. Figure S2A: Positive ion mode; Controls vs. PPMS.
A permutation test performed with 100 random permutations on the generated OPLS-DA model showed no
overfitting of the model (Q2 = (0.0, −0.557)). Figure S2B: Positive ion mode; Controls vs. SPMS. A permutation test
performed with 100 random permutations on the generated OPLS-DA model showed no overfitting of the model
(Q2 = (0.0, −0.517)). Figure S2C: Positive ion mode; PPMS vs. SPMS. A permutation test performed with 100
random permutations on the generated OPLS-DA model showed no overfitting of the model (Q2 = (0.0, −0.512)).
Figure S3A: Negative ion mode; Controls-PPMS. A permutation test performed with 100 random permutations on
the generated OPLS-DA model showed no overfitting of the model (Q2 = (0.0, −0.546)). Figure S3B: Negative ion
mode; Controls-SPMS. A permutation test performed with 100 random permutations on the generated OPLS-DA
model showed no overfitting of the model (Q2 = (0.0, −0.557)). Figure S3C: Negative ion mode; PPMS-SPMS.
A permutation test performed with 100 random permutations on the generated OPLS-DA model showed no
overfitting of the model (Q2 = (0.0, −0.512)). Table S1: Patient Demographics of control, PPMS, and SPMS groups.
Samples are sorted by groups: controls (n = 8), PPMS (n = 9), SPMS (n = 7). Excel file Table S2a,b: Raw abundances
of ions/features used to create the Venn diagrams in Figure 3. Table S3: Correlation analysis of lipids with sex,
age, PMI.
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